Marker Therapeutics Awarded $9.5 Mln Grant From CPRIT For MT-601 In Metastatic Pancreatic Cancer

(RTTNews) - Immuno-oncology company Marker Therapeutics, Inc. (MRKR) announced Tuesday that the Company has been awarded a $9.5 million grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to support the clinical investigation of MT-601 in patients with metastatic pancreatic cancer.

The CPRIT grant is intended to support the Company's Phase 1 PANACEA study evaluating the safety and tolerability of MT-601, a multi-tumor associated antigen (multiTAA)-specific T cell product, in patients with metastatic pancreatic cancer.

The Company's lead asset, MT-601, is currently being studied in patients with CD19-CAR relapsed lymphoma as the primary indication.

Due to the broad target recognition profile of MT-601, the Company plans to investigate its potential application beyond lymphoma in patients with solid tumors.

The use of MT-601 in solid tumors is supported by preliminary efficacy data of a previous study conducted at Baylor College of Medicine investigating multiTAA-specific T cells in patients with pancreatic cancer who received treatment in conjunction with frontline chemotherapy

Including this CPRIT grant, the Company has been awarded over $30 million in non-dilutive funding from governmental institutions including FDA, NIH and CPRIT.